Michael Karl Melzer

Number and proportion of cell types identified by single-nucleus multiomic analysis.

CRISPR/Cas9 guide RNA sequences used in this study.

Marker expression, pathway enrichment, and inferred trajectory analyses of fibroblast subpopulations identified in KPC and AKPC tumors.

Survival, epithelial marker staining, cell morphology, viability, and DNA damage-associated readouts in KPC and AKPC models.

Transcription factor, pathway enrichment, and proteomic analyses comparing KPC and AKPC tumor cells.

Immune marker staining, collagen features, and αSMA-associated stromal analyses in KC/AKC and KPC/AKPC tumors.

Analyses of TGFβ ligand/receptor expression, reporter activity, inferred signaling interactions, and PSC differentiation in ATM-deficient tumor models.

PSC differentiation assays using co-culture and conditioned medium approaches, and PUB-based systems in mouse and human ATM-deficient tumor models.

Clustering, quality control metrics, and immune cell subset annotation from single-nucleus multiomic profiling of KPC and AKPC tumors.

Deconvolution benchmarking, ATR perturbation experiments (ROS measurement and PSC differentiation), and patient-derived model assessing chemotherapy response after tumor–CAF signaling perturbation in an ATR-mutant context.